510(k) · Cleared
ClearedArchitect Cortisol Assay
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Seradyn, Inc. · JFT Fluorometric, Cortisol
Cleared on Sep 22, 2006 as substantially equivalent to K033731 (Fujirebio Diagnostics,Inc., 2004) after a 52-day review. Its family tree reaches back 1 generation to 2004. 1 later device descends from it.
- Decided
- Sep 22, 2006
- Review
- 52 days
- Class
- Class II
- Product code
- JFT
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to K033731 (2004). 1 later device descends from it, 1 citing it directly.
Most influential descendants
Showing 1 of 1 · See all- K242505Elecsys Cortisol IIIRoche Diagnostics · 2025 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | K033731 | Axsym Cortisol Assay | Fujirebio Diagnostics,Inc. | 2004 | — |
| 0 (this device) | K062204 | Architect Cortisol Assay | Seradyn, Inc. | 2006 | — |
| +1 | K242505 | Elecsys Cortisol III | Roche Diagnostics | 2025 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2025 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in JFT? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new JFT device
- #1 K242505 Elecsys Cortisol IIIscore 10.0 · 2 generations · no Class I recall
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K033731 | Axsym Cortisol AssaySummary page 1…antitative determination of cortisol in human serum, plasma or urine. Legally marketed device to which equivalency is claimed AXSYM ® CORTISOL REAGENTS AND CALIBRATORS (K033731) DESCRIPTION OF DEVICE The ARCHITECT Cortisol assay is a delayed one-step immunoassay for the quantitative determination of cort… | 2004 |
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K242505 | Elecsys Cortisol III | 2025 | 0 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Its one ancestor has no recall.
- Of its descendants, K242505 (Roche Diagnostics, 2025) has gone furthest, with 0 descendants of its own.
How does its category compare?
All JFT devicesJFT Fluorometric, Cortisol: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · JFT
1in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · JFT
Too few JFT 510(k)s in any year since 2007 to give a median.
Recalls per year · JFT
1in 2012
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · JFT
9in 2025
MAUDE reports naming product code JFT, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 1 |
| 2012 | 0 | — | 1 | 16 |
| 2013 | 0 | — | 0 | 6 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 1 | — | 0 | 0 |
| 2016 | 1 | — | 0 | 2 |
| 2017 | 0 | — | 0 | 4 |
| 2018 | 0 | — | 0 | 3 |
| 2019 | 1 | — | 0 | 6 |
| 2020 | 0 | — | 0 | 4 |
| 2021 | 0 | — | 0 | 2 |
| 2022 | 0 | — | 0 | 2 |
| 2023 | 0 | — | 0 | 9 |
| 2024 | 0 | — | 0 | 5 |
| 2025 | 1 | — | 0 | 9 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
ARCHITECT Cortisol is a chemiluminescent microparticle immunoassay (CMIA)
for the quantitative determination of cortisol in human serum, plasma or urine on
the ARCHITECT i System. The ARCHITECT Cortisol assay is intended for use
as an aid in the diagnosis and treatment of adrenal disorders.
The ARCHITECT Cortisol Calibrators are for the calibration of the ARCHITECT i
System when used for the quantitative determination of cortisol in human serum,
plasma or urine.
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K062204 · printed Nov 4, 2026
Cite this page
510(k) Report. “K062204: Architect Cortisol Assay.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K062204
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026